We define the onset of the latent phase of CML when the BCR::ABL1 gene is acquired by one HSC, and this phase ends when the blast cells in the bloodstream reach 3%. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.